Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2020 Sep 1;130(9):5027. doi: 10.1172/JCI142404

Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2

Jia Wang, Peng Cheng, Marat S Pavlyukov, Hai Yu, Zhuo Zhang, Sung-Hak Kim, Mutsuko Minata, Ahmed Mohyeldin, Wanfu Xie, Dongquan Chen, Violaine Goidts, Brendan Frett, Wenhao Hu, Hongyu Li, Yong Jae Shin, Yeri Lee, Do-Hyun Nam, Harley I Kornblum, Maode Wang, Ichiro Nakano
PMCID: PMC7456217  PMID: 32870163

Original citation: J Clin Invest. 2017;127(8):3075–3089. https://doi.org/10.1172/JCI89092

Citation for this expression of concern: J Clin Invest. 2020;130(9):5027. https://doi.org/10.1172/JCI142404

The Editors recently became aware of potential blot anomalies in Figures 1J, 2A, 3A, and 4D and Supplemental Figures 3A, 4C, and 6A. The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.

Version 1. 09/01/2020

Print issue publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES